Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹8,114 Cr
down ₹243 Cr vs Aug 2025
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In September 2025 it disclosed 37 stocks worth ₹8,114 Cr, down ₹243 Cr from Aug 2025. Its largest positions were Sun Pharmaceutical Industries Limited (12.3%), Lupin Limited (7.3%), Divi's Laboratories Limited (7.0%); the ten largest together made up 58.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 75.8% of its equity. Cash and debt stood at 0.5%. Compared with Aug 2025 the fund entered 0 new stocks and exited 0.
Against 226 other Sectoral / Thematic funds
Concentration
79%
Top-10 weight is higher than 79% of peers
Breadth
34%
Holds more stocks than 34% of peers
Cash
7%
Holds more cash than 7% of peers
What these mean: concentration · cash
Holdings in September 2025
Download CSVEvery line the fund disclosed, with the change against Aug 2025. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 12.29% | up 0.36 pts | ₹997 Cr | down ₹13 L | Held |
| Lupin Limited | 7.26% | up 1.18 pts | ₹589 Cr | up ₹80.9 Cr | Added |
| Divi's Laboratories Limited | 7.01% | down 0.32 pts | ₹569 Cr | down ₹44.2 Cr | Trimmed |
| Cipla Limited | 6.48% | up 0.39 pts | ₹525 Cr | up ₹16.8 Cr | Added |
| Apollo Hospitals Enterprise Limited | 5.92% | up 0.02 pts | ₹481 Cr | down ₹13 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 5.91% | up <0.01 pts | ₹479 Cr | down ₹14.3 Cr | Trimmed |
| Vijaya Diagnostic Centre Limited | 3.56% | up 0.08 pts | ₹289 Cr | down ₹2.3 Cr | Trimmed |
| MedPlus Health Services Limited | 3.39% | down 0.27 pts | ₹275 Cr | down ₹30.7 Cr | Trimmed |
| Gland Pharma Limited | 3.24% | up 0.28 pts | ₹263 Cr | up ₹15.9 Cr | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 2.99% | down 0.05 pts | ₹243 Cr | down ₹11.4 Cr | Trimmed |
| Ajanta Pharma Limited | 2.85% | up <0.01 pts | ₹231 Cr | down ₹6.8 Cr | Trimmed |
| Sai Life Sciences Limited | 2.71% | up 0.19 pts | ₹220 Cr | up ₹9.2 Cr | Added |
| Abbott India Limited | 2.48% | down 0.11 pts | ₹201 Cr | down ₹15 Cr | Trimmed |
| Dr. Lal Path Labs Limited | 2.34% | down 0.07 pts | ₹190 Cr | down ₹11.6 Cr | Trimmed |
| Aurobindo Pharma Limited | 2.27% | up 0.18 pts | ₹185 Cr | up ₹9.5 Cr | Added |
| Mankind Pharma Limited | 2.27% | up 0.03 pts | ₹185 Cr | down ₹2.7 Cr | Trimmed |
| Thyrocare Technologies Limited | 2.25% | down 0.38 pts | ₹183 Cr | down ₹36.8 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 2.20% | up 0.04 pts | ₹179 Cr | down ₹1.7 Cr | Trimmed |
| Alkem Laboratories Limited | 2.16% | up 0.11 pts | ₹176 Cr | up ₹3.9 Cr | Added |
| JB Chemicals & Pharmaceuticals Limited | 2.11% | up 0.04 pts | ₹171 Cr | down ₹1.5 Cr | Trimmed |
| Biocon Limited | 1.98% | up 0.22 pts | ₹161 Cr | up ₹13.7 Cr | Added |
| Pfizer Limited | 1.98% | up 0.01 pts | ₹160 Cr | down ₹3.8 Cr | Trimmed |
| Suraksha Diagnostic Limited | 1.43% | up 0.04 pts | ₹116 Cr | up ₹2 L | Held |
| IPCA Laboratories Limited | 1.35% | up 0.05 pts | ₹110 Cr | up ₹1.1 Cr | Added |
| Torrent Pharmaceuticals Limited | 1.35% | up 0.05 pts | ₹109 Cr | up ₹1.3 Cr | Added |
| Sanofi India Limited | 1.32% | down 0.10 pts | ₹107 Cr | down ₹11.4 Cr | Trimmed |
| Fortis Healthcare Limited | 1.32% | up 0.12 pts | ₹107 Cr | up ₹6.4 Cr | Added |
| Sanofi Consumer Healthcare India Limited | 1.24% | down 0.08 pts | ₹101 Cr | down ₹9.9 Cr | Trimmed |
| Anthem Biosciences Limited | 0.99% | down 0.04 pts | ₹80.6 Cr | down ₹6 Cr | Trimmed |
| Syngene International Limited | 0.98% | up 0.02 pts | ₹79.8 Cr | down ₹39 L | Held |
| Akums Drugs and Pharmaceuticals Limited | 0.82% | up <0.01 pts | ₹66.9 Cr | down ₹1.9 Cr | Trimmed |
| Emcure Pharmaceuticals Limited | 0.74% | down 0.04 pts | ₹60.2 Cr | down ₹5.3 Cr | Trimmed |
| AstraZeneca Pharma India Limited | 0.70% | up 0.07 pts | ₹57 Cr | up ₹4 Cr | Added |
| Indoco Remedies Limited | 0.66% | up 0.07 pts | ₹53.6 Cr | up ₹4.7 Cr | Added |
| Cash, TREPS & receivables | 0.53% | up 0.01 pts | ₹42.7 Cr | down ₹72 L | Trimmed |
| Orchid Pharma Limited | 0.43% | down 0.01 pts | ₹34.6 Cr | down ₹1.6 Cr | Trimmed |
| Zydus Lifesciences Limited | 0.23% | down 2.11 pts | ₹19.1 Cr | down ₹177 Cr | Trimmed |
| Concord Biotech Limited | 0.23% | up <0.01 pts | ₹18.4 Cr | down ₹38 L | Trimmed |
What changed, Aug 2025 to Sep 2025
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Lupin Limitedup ₹80.9 Cr (+1.18% pts)
- Cipla Limitedup ₹16.8 Cr (+0.39% pts)
- Gland Pharma Limitedup ₹15.9 Cr (+0.28% pts)
- Biocon Limitedup ₹13.7 Cr (+0.22% pts)
- Aurobindo Pharma Limitedup ₹9.5 Cr (+0.18% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Aug 2025, the weight rose most in Pharmaceuticals & Biotechnology (+0.3 pts), and fell most in Retailing (−0.3 pts) and Healthcare Services (−0.1 pts).
- Pharmaceuticals & Biotechnology75.5% → 75.8%+0.3 pts
- Retailing3.7% → 3.4%−0.3 pts
- Healthcare Services20.2% → 20.1%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Sep 2022 | Sep 2024 | Mar 2025 | Jun 2025 | Aug 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 80.0% | 79.0% | 77.1% | 75.4% | 75.5% | 75.8% |
| Healthcare Services | 18.3% | 17.8% | 18.9% | 20.0% | 20.2% | 20.1% |
| Retailing | — | 2.4% | 3.4% | 3.8% | 3.7% | 3.4% |
| Pharmaceuticals | 1.3% | 0.8% | 0.5% | 0.7% | 0.6% | 0.7% |
Allocation in Sep 2025change vs Aug 2025
- Pharmaceuticals & Biotechnology (27)75.8%▲ 0.3 pts
- Healthcare Services (8)20.1%▼ 0.1 pts
- Retailing (1)3.4%▼ 0.3 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Sep 2025
0.5%
unchanged vs Aug 2025
- Cash alone
- 0.6%
- cash and net receivables
- A year earlier
- 3.7%
- Sep 2024 · now ▼ 3.2 pts
- Last 12 months
- 0.3% – 4.4%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.